These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
572 related articles for article (PubMed ID: 23551568)
21. Six year experience of external beam radiotherapy, brachytherapy boost with a 1Ci (192)Ir source, and neoadjuvant hormonal manipulation for prostate cancer. Izard MA; Haddad RL; Fogarty GB; Rinks A; Dobbins T; Katelaris P Int J Radiat Oncol Biol Phys; 2006 Sep; 66(1):38-47. PubMed ID: 16904516 [TBL] [Abstract][Full Text] [Related]
22. Three-year results of treatment for prostate cancer with low-dose rate temporary iridium-192 brachytherapy. Momma T; Saito S; Toya K; Yorozu A; Dokiya T; Murai M Int J Urol; 2006 Mar; 13(3):218-23. PubMed ID: 16643612 [TBL] [Abstract][Full Text] [Related]
23. Long-term results of a prospective, Phase II study of long-term androgen ablation, pelvic radiotherapy, brachytherapy boost, and adjuvant docetaxel in patients with high-risk prostate cancer. Dibiase SJ; Hussain A; Kataria R; Amin P; Bassi S; Dawson N; Kwok Y Int J Radiat Oncol Biol Phys; 2011 Nov; 81(3):732-6. PubMed ID: 21036486 [TBL] [Abstract][Full Text] [Related]
24. Early quality of life outcomes in patients with prostate cancer managed by high-dose-rate brachytherapy as monotherapy. Komiya A; Fujiuchi Y; Ito T; Morii A; Yasuda K; Watanabe A; Nozaki T; Iida H; Nomura K; Fuse H Int J Urol; 2013 Feb; 20(2):185-92. PubMed ID: 22905941 [TBL] [Abstract][Full Text] [Related]
25. Comparison of the outcome and morbidity for localized or locally advanced prostate cancer treated by high-dose-rate brachytherapy plus external beam radiotherapy (EBRT) versus EBRT alone. Fang FM; Wang YM; Wang CJ; Huang HY; Chiang PH Jpn J Clin Oncol; 2008 Jul; 38(7):474-9. PubMed ID: 18621848 [TBL] [Abstract][Full Text] [Related]
26. High-dose-rate brachytherapy as a monotherapy for favorable-risk prostate cancer: a Phase II trial. Barkati M; Williams SG; Foroudi F; Tai KH; Chander S; van Dyk S; See A; Duchesne GM Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):1889-96. PubMed ID: 21550182 [TBL] [Abstract][Full Text] [Related]
27. Long-term outcome and toxicity of salvage brachytherapy for local failure after initial radiotherapy for prostate cancer. Burri RJ; Stone NN; Unger P; Stock RG Int J Radiat Oncol Biol Phys; 2010 Aug; 77(5):1338-44. PubMed ID: 20138442 [TBL] [Abstract][Full Text] [Related]
28. A new model using number of needles and androgen deprivation to predict chronic urinary toxicity for high or low dose rate prostate brachytherapy. Vargas C; Ghilezan M; Hollander M; Gustafson G; Korman H; Gonzalez J; Martinez A J Urol; 2005 Sep; 174(3):882-7. PubMed ID: 16093980 [TBL] [Abstract][Full Text] [Related]
29. Salvage HDR brachytherapy for recurrent prostate cancer after previous definitive radiation therapy: 5-year outcomes. Chen CP; Weinberg V; Shinohara K; Roach M; Nash M; Gottschalk A; Chang AJ; Hsu IC Int J Radiat Oncol Biol Phys; 2013 Jun; 86(2):324-9. PubMed ID: 23474112 [TBL] [Abstract][Full Text] [Related]
30. High-dose-rate interstitial brachytherapy as monotherapy for clinically localized prostate cancer: treatment evolution and mature results. Zamboglou N; Tselis N; Baltas D; Buhleier T; Martin T; Milickovic N; Papaioannou S; Ackermann H; Tunn UW Int J Radiat Oncol Biol Phys; 2013 Mar; 85(3):672-8. PubMed ID: 22929859 [TBL] [Abstract][Full Text] [Related]
31. A comparison of the impact of isotope ((125)I vs. (103)Pd) on toxicity and biochemical outcome after interstitial brachytherapy and external beam radiation therapy for clinically localized prostate cancer. Kollmeier MA; Pei X; Algur E; Yamada Y; Cox BW; Cohen GN; Zaider M; Zelefsky MJ Brachytherapy; 2012; 11(4):271-6. PubMed ID: 22192495 [TBL] [Abstract][Full Text] [Related]
32. Hypofractionated conformal HDR brachytherapy in hormone naïve men with localized prostate cancer. Is escalation to very high biologically equivalent dose beneficial in all prognostic risk groups? Galalae RM; Martinez A; Nuernberg N; Edmundson G; Gustafson G; Gonzalez J; Kimming B Strahlenther Onkol; 2006 Mar; 182(3):135-41. PubMed ID: 16520907 [TBL] [Abstract][Full Text] [Related]
33. Prostate-specific antigen relapse-free survival in patients with localized prostate cancer treated by brachytherapy. Joseph J; Al-Qaisieh B; Ash D; Bottomley D; Carey B BJU Int; 2004 Dec; 94(9):1235-8. PubMed ID: 15610096 [TBL] [Abstract][Full Text] [Related]
34. Radical prostatectomy versus external-beam radiotherapy for localized prostate cancer: long-term effect on biochemical control-in search of the optimal treatment. González-San Segundo C; Herranz-Amo F; Alvarez-González A; Cuesta-Álvaro P; Gómez-Espi M; Paños-Fagundo E; Santos-Miranda JA Ann Surg Oncol; 2011 Oct; 18(10):2980-7. PubMed ID: 21431406 [TBL] [Abstract][Full Text] [Related]
35. Intermediate-risk localized prostate cancer in the PSA era: radiotherapeutic alternatives. Gondi V; Deutsch I; Mansukhani M; O'Toole KM; Shah JN; Schiff PB; Katz AE; Benson MC; Goluboff ET; Ennis RD Urology; 2007 Mar; 69(3):541-6. PubMed ID: 17382161 [TBL] [Abstract][Full Text] [Related]
36. Management of localised prostate cancer: watchful waiting, surgery or radiation therapy, depending on the natural course, which is often relatively slow. Prescrire Int; 2012 Oct; 21(131):242-8. PubMed ID: 23185849 [TBL] [Abstract][Full Text] [Related]
37. Brachytherapy in men aged < or = 54 years with clinically localized prostate cancer. Merrick GS; Wallner KE; Butler WM; Galbreath RW; Allen ZA; Adamovich E; True L BJU Int; 2006 Aug; 98(2):324-8. PubMed ID: 16879672 [TBL] [Abstract][Full Text] [Related]
38. Prostate-specific antigen relapse-free survival and side-effects in 734 patients with up to 10 years of follow-up with localized prostate cancer treated by permanent iodine implants. Prada PJ; Juan G; González-Suárez H; Fernández J; Jimenez I; Amón J; Cepeda M BJU Int; 2010 Jul; 106(1):32-6. PubMed ID: 20067460 [TBL] [Abstract][Full Text] [Related]
39. Unification of a common biochemical failure definition for prostate cancer treated with brachytherapy or external beam radiotherapy with or without androgen deprivation. Fitch DL; McGrath S; Martinez AA; Vicini FA; Kestin LL Int J Radiat Oncol Biol Phys; 2006 Dec; 66(5):1430-9. PubMed ID: 16765527 [TBL] [Abstract][Full Text] [Related]
40. Erectile function after brachytherapy with external beam radiation for prostate cancer. Fujioka H; Ishimura T; Sakai Y; Fujii T; Jo Y; Takenaka A; Fujisawa M Arch Androl; 2004; 50(4):295-301. PubMed ID: 15277008 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]